ライフサイエンスコーパス: bowel

1 ith extensive fibrostenosing CD of the small bowel.

2 0.001), spleen (28% +/- 13%, P = 0.001), and bowel (44% +/- 13%, P < 0.001).

3 Conclusion Bowel abnormalities and gallbladder bile stasis were com

4 al management of CD patients with mild small-bowel active disease.

5 between mucosal healing risk of future small bowel adenocarcinoma (HR, 0.18; 95% CI, 0.02-1.61), alth

6 Corresponding HRs were small bowel adenocarcinoma 3.05 (95% confidence interval [CI],

7 Overall, there was 1 extra case of small bowel adenocarcinoma in every 2944 patients with CD foll

8 tients (0.06%) received a diagnosis of small bowel adenocarcinoma vs 45 reference individuals (0.02%)

9 n to calculate hazard ratios (HRs) for small bowel adenocarcinoma, adenomas, and carcinoids.

10 ference, -10.1 [95% CI, -14.6 to -5.7]), and bowel (adjusted mean difference, -5.0 [95% CI, -7.6 to -

11 nterventions such as swallowing assessments, bowel and bladder care, mobility assessments, and consis

12 The small bowel and colon are the sites most commonly involved.

13 to the gastrointestinal tract, mainly small bowel and colon.

14 sly shown that CDNF is also expressed in the bowel and that its absence leads to degeneration and aut

15 Endometriosis of the bowel and urinary tract are types of extragenital endome

16 for infiltrating endometriosis involving the bowel and urinary tract on abdominal ultrasonography and

17 tary diagnostic work-up focused on the small-bowel between June 2017 and June 2018.

18 ars, from "old" ones such as suspected small bowel bleeding (still the main indication for SBCE) to n

19 hronic inflammatory diseases that affect the bowel, but its pathogenesis is yet to be completely defi

20 chanisms include water trapping in the small bowel by viscous fibers and delivery of substrates to th

21 The database used for the NHS Bowel Cancer Screening Programme (BCSP) derives particip

22 n made between celiac disease (CD) and small bowel cancers, but there have been no detailed studies o

23 atients [14.4% of patients with jejuno-ileal bowel CD; 31 females; median age 36 (12-69) years] under

24 panoramic 344 degrees -view increases small-bowel CE accuracy, thereby improving the clinical manage

25 s better rate of tolerability and comparable bowel cleanliness when compared to larger volume prepara

26 id not report any significant differences in bowel complaints in the first week, after 3 weeks, or in

27 A few hours later, bowel content could be detected in the tube and an abdom

28 ased from enteroendocrine cells of the small bowel, contribute to obesity and comorbid conditions.

29 hnique to address severe and extensive small bowel Crohn's disease presenting with 3 severely fibroti

30 scores that incorporate prognostic factors, bowel damage assessment and non-invasive close monitorin

31 be regarded as a new standard for both small-bowel diagnosis and monitoring in inflammatory bowel dis

32 65%) matched controls developed inflammatory bowel disease (adjusted HR, 3.29; 95% confidence interva

33 frican American population with inflammatory bowel disease (IBD) and Non-IBD/Non-Infectious Colitis (

34 ified by the high prevalence of inflammatory bowel disease (IBD) and the even higher occurrence of su

35 observed both in patients with inflammatory bowel disease (IBD) and those with experimental colitis.

36 Patients with inflammatory bowel disease (IBD) are at increased risk of invasive pn

37 mes from four human cohorts: an inflammatory bowel disease (IBD) cohort, an obese cohort and two popu

38 lcerative colitis (UC), and non-inflammatory bowel disease (IBD) controls.

39 The increased incidence of inflammatory bowel disease (IBD) has become a global phenomenon that

40 nts in patients with cancer and inflammatory bowel disease (IBD) has not been well described.

41 Patients with inflammatory bowel disease (IBD) have an increased risk of colorectal

42 Studies of inflammatory bowel disease (IBD) have been inconclusive in relating m

43 itable bowel syndrome (IBS) and inflammatory bowel disease (IBD) intersect to form a scantily defined

44 Inflammatory bowel disease (IBD) is a chronic disorder characterized

45 Inflammatory bowel disease (IBD) is a chronic immune-mediated disease

46 Inflammatory bowel disease (IBD) is a chronic inflammatory disease as

47 Inflammatory bowel disease (IBD) is a common chronic inflammatory con

48 Inflammatory bowel disease (IBD) is a complex genetic disease that is

49 Inflammatory bowel disease (IBD) is a debilitating chronic disease wi

50 oscopy for clinically suspected inflammatory bowel disease (IBD) is not well defined, and its correla

51 Pregnant women with inflammatory bowel disease (IBD) may require biologic or thiopurine t

52 stinal manifestations (EIMs) in inflammatory bowel disease (IBD) patients, and they are responsible f

53 owever, the function of Arg1 in inflammatory bowel disease (IBD) remains poorly characterized.

54 RS) may soon be used to predict inflammatory bowel disease (IBD) risk in prevention efforts.

55 ase (CD) is a chronic relapsing inflammatory bowel disease (IBD) that may be marked by debilitating s

56 associated with the severity of inflammatory bowel disease (IBD)(2,5), the diverse immunomodulatory p

57 CRC), colonic lesions caused by inflammatory bowel disease (IBD), and normal thickened colon wall (NT

58 s a major clinical challenge in inflammatory bowel disease (IBD), due, in part, to insufficient under

59 ses of the intestine, including inflammatory bowel disease (IBD), graft-versus-host disease (GVHD), a

60 Inflammatory bowel disease (IBD), including Crohn's disease (CD) and

61 has been used for patients with inflammatory bowel disease (IBD), who have failed azathioprine (AZA)

62 langitis (PSC) in patients with inflammatory bowel disease (IBD).

63 ontrols (HCs) and patients with inflammatory bowel disease (IBD).

64 a novel susceptibility gene for inflammatory bowel disease (IBD).

65 ntributes to the development of inflammatory bowel disease (IBD).

66 down-regulated in patients with inflammatory bowel disease (IBD).

67 duces gut symptoms in quiescent inflammatory bowel disease (IBD).

68 ant role in the pathogenesis of inflammatory bowel disease (IBD).

69 in macrophages (Mphis) leads to inflammatory bowel disease (IBD).

70 yalgia rheumatica (n = 25,581), inflammatory bowel disease (n = 27,739), rheumatoid arthritis (n = 25

71 Very early onset inflammatory bowel disease (VEOIBD) denotes children with onset of IB

72 macrophages from patients with inflammatory bowel disease [IBD]) or mouse macrophages, respectively.

73 abolic pathways associated with inflammatory bowel disease across two completely independent studies.

74 isotype, whereas patients with inflammatory bowel disease also produce high concentrations of IgG.

75 Inflammatory bowel disease also was more common before a confirmed Ig

76 taining susceptibility loci for inflammatory bowel disease and chronic pancreatitis are associated wi

77 isk factor for pCCA followed by inflammatory bowel disease and cirrhosis, whereas other liver disease

78 regulation of DUOX2 and NOX1 in inflammatory bowel disease and colorectal cancer.

79 role in conditions ranging from inflammatory bowel disease and HIV through to sepsis and malnutrition

80 tool of pediatric patients with inflammatory bowel disease and in tissue sections of patients with CD

81 ediated diseases, most commonly inflammatory bowel disease and rheumatoid arthritis.

82 gitis, which is associated with inflammatory bowel disease and with an increased incidence of hepatob

83 d, notably, to some humans with inflammatory bowel disease as a therapeutic agent that modulates infl

84 ed age and diagnoses other than inflammatory bowel disease as significant risk factors for mortality.

85 pathy have an increased risk of inflammatory bowel disease both before and after their nephropathy di

86 lusion criteria were studies of inflammatory bowel disease cohorts, referrals for difficult polypecto

87 Inflammatory bowel disease data and ESKD status were obtained through

88 ropathy patients had an earlier inflammatory bowel disease diagnosis compared with 220 (1.09%) contro

89 with IgA nephropathy, comorbid inflammatory bowel disease elevates the risk of progression to ESKD.

90 he relationship between PSC and inflammatory bowel disease has inspired theories that intestinal fact

91 Patients with inflammatory bowel disease have been shown to have abnormal brain mor

92 ere made in 2 patients (1%) and inflammatory bowel disease in 2 patients (1%).

93 ns in FAMIN cause arthritis and inflammatory bowel disease in early childhood, and a common genetic v

94 on cause serious infections and inflammatory bowel disease in glycogen storage disease type Ib (GSD-I

95 , the arthritis associated with inflammatory bowel disease including Crohn's disease and ulcerative c

96 suppressive therapy, such as in inflammatory bowel disease including ulcerative colitis and Crohn's d

97 genic or protective role during inflammatory bowel disease is controversial.

98 sodium sulfate-induced chronic inflammatory bowel disease model, with efficacy similar to positive-c

99 or there is a family history of inflammatory bowel disease or coeliac disease.

100 ncontrolled inflammation due to inflammatory bowel disease or eosinophilic gastrointestinal disease s

101 -onset patients followed at our Inflammatory Bowel Disease outpatient clinic and compare with adult-o

102 f ileal biopsies and PBMCs from inflammatory bowel disease patients, we identified a positive correla

103 en procedures for neoplasia and inflammatory bowel disease patients.

104 ive colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC (P = 0.0029,

105 correlated with reduction of an inflammatory bowel disease risk gene ATG16L1 and Paneth cell lysozyme

106 Crohn's disease is an inflammatory bowel disease that is characterized by chronic inflammat

107 ines how targeting RORgammat in inflammatory bowel disease therapy could influence the development of

108 1.33 to 2.55) demonstrated that inflammatory bowel disease was associated with increased ESKD risk in

109 No deaths or cases of inflammatory bowel disease were reported.

110 g of the intestinal wall, secondary signs of bowel disease within the surrounding mesentery, and abno

111 s like rheumatoid arthritis and inflammatory bowel disease yet increases susceptibility to tuberculos

112 as high as 78% in patients with inflammatory bowel disease(2).

113 kidney disease, 3.9% (n=18) and inflammatory bowel disease, 21.9% (n=101).

114 multiple sclerosis, psoriasis, inflammatory bowel disease, among others) and in the host response to

115 uding irritable bowel syndrome, inflammatory bowel disease, and colorectal cancer.

116 breast cancer, type 2 diabetes, inflammatory bowel disease, and coronary heart disease, all of which

117 ystemic lupus erythematosus and inflammatory bowel disease, and our previous work suggests that dysre

118 ein claudin-2 is upregulated in inflammatory bowel disease, and yet its deficit worsens infectious an

119 ents as malabsorption syndrome, inflammatory bowel disease, anorexia nervosa, and intestinal pseudo-o

120 influencing type 2 diabetes and inflammatory bowel disease, making them good candidates for whole-exo

121 TL1A, TNFSF15) is implicated in inflammatory bowel disease, modulating the location and severity of i

122 Male sex, young age at onset, small bowel disease, more active disease, and diagnostic delay

123 e in various diseases including inflammatory bowel disease, neurologic diseases, cardiovascular disor

124 ailure, chronic kidney disease, inflammatory bowel disease, patient blood management in the periopera

125 high-risk patients (those with inflammatory bowel disease, previous CRC, previous multiple large pol

126 , systemic lupus erythematosus, inflammatory bowel disease, psoriasis, Sjogren syndrome, coronary art

127 Older age at presentation, small bowel disease, serology (anti-Saccharomyces cerevisiae a

128 In patients with inflammatory bowel disease, there is a breakdown of the multiple stra

129 alectin that has been linked to inflammatory bowel disease, within the context of the murine intestin

130 from the 2015 and 2017 Adelphi Inflammatory Bowel Disease-Specific Programme (IBD-DSP) were used.

131 the detection and follow-up of inflammatory bowel disease.

132 Galectin-9 is a risk gene in inflammatory bowel disease.

133 ich diet modulates the onset of inflammatory bowel disease.

134 for therapeutic intervention in inflammatory bowel disease.

135 linked to pathologies including inflammatory bowel disease.

136 S in HIV-negative patients with inflammatory bowel disease.

137 nce of childbearing for risk of inflammatory bowel disease.

138 flammatory conditions including inflammatory bowel disease.

139 tial diagnosis and follow-up of inflammatory bowel disease.

140 inflammatory conditions such as inflammatory bowel disease.

141 n cancer (CAC) in patients with inflammatory bowel disease.

142 ne-mediated diseases, including inflammatory bowel disease.

143 of microbiotas from humans with inflammatory bowel disease.

144 a morphology code suggestive of inflammatory bowel disease.

145 SE patients do not develop significant small bowel disease.

146 (23.2%) and family history with inflammatory bowel diseases (9.4%) and celiac disease (7.3%) were hig

147 and 10 newborn infants without inflammatory bowel diseases (controls) and 8 infants with necrotizing

148 Inflammatory Bowel Diseases (IBD) affect psychological, family, socia

149 Inflammatory bowel diseases (IBD) are associated with alterations in

150 Children with inflammatory bowel diseases (IBD) are particularly vulnerable to infe

151 linical outcomes of adults with inflammatory bowel diseases (IBD).

152 dysregulation in patients with inflammatory bowel diseases (IBDs) and differences in inflammatory re

153 een proposed as a treatment for inflammatory bowel diseases (IBDs), but there are no established asso

154 Inflammatory bowel diseases (IBDs), including Crohn's disease and ulc

155 flammation and diseases such as inflammatory bowel diseases (IBDs), is often associated with dysbiosi

156 This is particularly evident in inflammatory bowel diseases (IBDs), where clinical trials of fecal mi

157 unosuppression for treatment of inflammatory bowel diseases (IBDs).

158 healthy individuals at risk for inflammatory bowel diseases (pre-UC) who later developed UC (post-UC)

159 eing developed for treatment of inflammatory bowel diseases and other immune-mediated diseases.

160 enetical evidence linking PD to inflammatory bowel diseases and we recently demonstrated that the neu

161 Inflammatory bowel diseases are associated with complex shifts in mic

162 ction have been associated with inflammatory bowel diseases, including ulcerative colitis (UC), but t

163 In particular, inflammatory bowel diseases, obesity, diabetes, asthma and chronic ob

164 ents with rheumatoid arthritis, inflammatory bowel diseases, psoriasis, or ankylosing spondylitis.

165 tal role in the pathogenesis of inflammatory bowel diseases-Crohn disease and ulcerative colitis-caus

166 ents at risk for development of inflammatory bowel diseases.

167 y apoptotic enterocolopathy and inflammatory bowel diseases.

168 which have also been linked to inflammatory bowel diseases.

169 ified as a gut damage marker in inflammatory bowel diseases.

170 ensitivity (VH) with underlying inflammatory bowel diseases.

171 n investigated in patients with inflammatory bowel diseases.

172 wel diagnosis and monitoring in inflammatory bowel diseases.

173 as cancer, cystic fibrosis, and inflammatory bowel diseases.

174 able Bowel Syndrome (PI-IBS) is a functional bowel disorder which has significant impacts to a patien

175 Collagenous colitis (CC) is an inflammatory bowel disorder with unknown etiopathogenesis involving H

176 syndrome with diarrhea, a common functional bowel disorder.

177 ographic distributions of Rome IV functional bowel disorders (FBDs) or their effects on quality of li

178 Rather, the emergent groups suggest that Bowel Disorders occur on a continuum of severity across

179 GI complications, including bowel distension, diarrhea, GI bleeding and ileus, were

180 psychometric properties and can be used for bowel dysfunction assessment in clinical and research se

181 paring surgery is oftentimes associated with bowel dysfunction complaints, namely the low anterior re

182 A striking expression of ACE2 on the small bowel enterocyte brush border supports intestinal infect

183 ically significant differences in urinary or bowel function and quality of life.

184 difference, -5.3 [95% CI, -8.2 to -2.4]) and bowel function at 1 year (adjusted mean difference, -4.1

185 BRT was associated with urinary, sexual, and bowel function changes not clinically different from act

186 s well as factors related to diet/lifestyle, bowel function, and medication were studied in relation

187 which are selected according to predominant bowel habit), as well as psychological therapies.

188 rinary tract symptoms, haematuria, change in bowel habit, hoarseness, fatigue, abdominal pain, lower

189 zed by abdominal pain, bloating, and erratic bowel habits.

190 atrophy, dysarthria, as well as urinary and bowel incontinence.

191 on to cultured explants of human aganglionic bowel induced proliferation of Schwann cells and formati

192 ellow discoloration of the bowel (n = 3) and bowel infarction (n = 2).

193 The replication capacity of RV in the small bowel is substantially due to its ability to inhibit dif

194 enting with 3 severely fibrotic and deformed bowel loops separated by 2 diseased segments with sequen

195 enting with 3 severely fibrotic and deformed bowel loops separated by 2 diseased segments with sequen

196 es) that can result in reduced blood flow to bowel loops.

197 trictureplasty, performed with discontinuous bowel loops.

198 This study aimed to investigate small-bowel motility and gut peptide responses to a standard t

199 confocal Z-stacks from persons without known bowel motility disorders.

200 Small-bowel motility, other MRI parameters, and glucagon-like

201 e identify alcohol consumption frequency and bowel movement quality as unexpectedly strong sources of

202 Patients with new-onset diarrhea (>=3 bowel movements in any 24-hour period in the 48 hours be

203 comes were clinical remission (clinical) and bowel mucosal damage (preclinical).

204 s associated with a significant reduction in bowel mucosal damage compared to placebo (standardized m

205 revealed unusual yellow discoloration of the bowel (n = 3) and bowel infarction (n = 2).

206 izing enterocolitis (NEC) is an inflammatory bowel necrosis of premature infants and an orphan diseas

207 ion of the primary tumor in metastatic small bowel neuroendocrine (SB-NET) remains controversial.

208 surgery on the development of adhesive small bowel obstruction (aSBO).

209 terize surgical outcomes for malignant small bowel obstruction (MaSBO) as compared to other small bow

210 Adhesive small bowel obstruction (SBO) remains one of the leading cause

211 is associated with increased risk for small bowel obstruction after laparoscopic gastric bypass surg

212 The main outcome was operation due to small bowel obstruction after the laparoscopic gastric bypass

213 The incidence rate of small bowel obstruction during pregnancy was 42.9 (95% CI 32.4

214 ogy of intussusception, the leading cause of bowel obstruction in infants, is unknown in most cases.

215 de receptor radionuclide therapy can lead to bowel obstruction in patients with mesenteric or periton

216 Small bowel obstruction is a common and feared long-term compl

217 The number of patients who developed bowel obstruction within 3 mo of a (177)Lu-DOTATATE trea

218 ollowing surgery or infection, and may cause bowel obstruction, chronic pain, or infertility.

219 were added to the final COS (12): mortality, bowel obstruction, intra-abdominal abscess, recurrent ap

220 struction (MaSBO) as compared to other small bowel obstructions (SBO) and to develop a prediction mod

221 e of rapid passage of nutrients to the small bowel, on the role of decreased gastric volume capacity

222 Staining intensity was high in small bowel (p = 0.04) and low in stomach (p = 0.004) NENs.

223 al adhesions are at potential higher risk of bowel perforation during implantation of an indwelling p

224 e that typhoid fever accounts for 43% of all bowel perforation during the period of enhanced surveill

225 evaluating the ability to completely finish bowel preparation and adverse effects (unpleasant taste,

226 tus has been shown to be a predictor of poor bowel preparation for colonoscopy; however, the optimal

227 The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopie

228 ration for colonoscopy; however, the optimal bowel preparation regimen for hospitalized patients is u

229 lon preparation quality, based on the Boston Bowel Preparation Scale, and a questionnaire given to al

230 Our aim was to compare the efficacy of bowel preparation volume size in hospitalized patients u

231 Bowel preparation was poor in 19% of index colonoscopies

232 ng patient instructions, mechanical and oral bowel preparation, chlorhexidine washes, and carbohydrat

233 with preoperative mechanical and antibiotic bowel preparation, skin washes, carbohydrate loading, an

234 and oral antibiotic (94% vs 27%, P < 0.001) bowel preparation.

235 ic strictureplasty (SSIS) and its effects on bowel preservation in Crohn disease (CD).

236 small numbers of thin sections from the same bowel region can produce varying results.

237 sociated with lower risk of subsequent small bowel related surgery (15.4% vs 40.3%, p < 0.001), with

238 We examined the impact of upfront small bowel resection (USBR) for metastatic SB-NET compared to

239 Associated strictureplasties and bowel resection were performed in 44% and 80%, respectiv

240 luded recurrent disease after previous small bowel resection, thickened mesentery, large inflammatory

241 a quarter of a century ago to avoid massive bowel resections in patients with extensive fibrostenosi

242 anastomosed with the proximal and the distal bowel, respectively.

243 second case was managed conservatively with bowel rest and intravenous antibiotics.

244 ted differences in patient-reported urinary, bowel, sexual, and hormonal function-Expanded Prostate C

245 Diagnostic Questionnaire, Rome III irritable bowel syndrome (IBS) and constipation questions, and the

246 The clinical spectra of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD

247 Nowadays irritable bowel syndrome (IBS) and lactose intolerance (LI) are tw

248 gree of overlap with dyspepsia and irritable bowel syndrome (IBS) in Nigeria, a typical African popul

249 Irritable bowel syndrome (IBS) is a common, symptom-based conditio

250 Irritable bowel syndrome (IBS) is a functional gastrointestinal di

251 Irritable bowel syndrome (IBS) is a heterogeneous disorder, but di

252 Irritable bowel syndrome (IBS) is characterized by abdominal pain,

253 that children suspected of having Irritable Bowel Syndrome (IBS) with Constipation (IBS-C) should be

254 Certain gut disorders, such as the irritable bowel syndrome (IBS), are associated with elevated level

255 t-brain interactions are common in irritable bowel syndrome (IBS), but the associations between neuro

256 with functional dyspepsia (FD) and irritable bowel syndrome (IBS), respectively, as defined by Rome I

257 owth (SIBO) may be associated with irritable bowel syndrome (IBS).

258 ysfunction have been implicated in irritable bowel syndrome (IBS).

259 itivity is common in patients with irritable bowel syndrome (IBS).

260 anagement of diarrhoea-predominant irritable bowel syndrome (IBS-D) is generally based on patient-rep

261 Post-infectious Irritable Bowel Syndrome (PI-IBS) is a functional bowel disorder w

262 the development of post-infectious Irritable Bowel Syndrome (PI-IBS).

263 Intestinal adaptation in short bowel syndrome (SBS) includes morphologic processes and

264 Short bowel syndrome (SBS) is a rare disease that results from

265 Many treatments for irritable bowel syndrome are available to those with the disease.

266 glutide use in pediatric patients with short bowel syndrome can aid in the achievement of enteral aut

267 or PN reduction in adult patients with short bowel syndrome compared with standard intestinal rehabil

268 BEST PRACTICE ADVICE 8: Although irritable bowel syndrome has been shown to respond to therapy with

269 Adults with short bowel syndrome have a high mortality and significant mor

270 transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-co

271 Irritable bowel syndrome is a functional gastrointestinal disorder

272 or is acute enteric infection, but irritable bowel syndrome is also more common in people with psycho

273 The pathophysiology of irritable bowel syndrome is incompletely understood, but it is wel

274 individuals, and participants with irritable bowel syndrome or Crohn's disease were more likely to ha

275 At 6 months, new diagnoses of irritable bowel syndrome were made in 2 patients (1%) and inflamma

276 roportion of people diagnosed with irritable bowel syndrome with diarrhea, a common functional bowel

277 s of bile acids (BAs), overlapping irritable bowel syndrome with diarrhoea (IBS-D).

278 ambulatory visits for symptomatic irritable bowel syndrome, chronic functional abdominal pain, const

279 common in some disorders, such as irritable bowel syndrome, Crohn's disease and pancreatitis.

280 gastrointestinal disorder, such as irritable bowel syndrome, functional dyspepsia, or functional cons

281 strointestinal diseases, including irritable bowel syndrome, inflammatory bowel disease, and colorect

282 esses such as neurodegeneration or irritable bowel syndrome.

283 antation in US pediatric patients with short bowel syndrome.

284 teduglutide in US adult patients with short bowel syndrome.

285 antation in the treatment of pediatric short bowel syndrome.

286 ng, water-with-solid gastric emptying, small-bowel transit, and colonic transit.

287 er (PTLD) is reported in the pediatric small bowel transplant (SBTx) population, which may be associa

288 culture-proven CDI, 12 after isolated small bowel Tx, 9 after liver-small bowel Tx, and 1 after mult

289 isolated small bowel Tx, 9 after liver-small bowel Tx, and 1 after multivisceral Tx.

290 e describes the techniques and modalities of bowel ultrasound, as well as the normal features of the

291 nds; left ventricle; liver; spleen; kidneys; bowel; urinary bladder; gluteus muscle; and malignant le

292 Indications and diagnostic yield of small-bowel video capsule endoscopy (SB-VCE) are communicated

293 sound, as well as the normal features of the bowel wall and contiguous structures.

294 Ultrasound can be used to evaluate the bowel wall and the elements that surround it without the

295 Median length of preserved small bowel was 50 (20-148) cm.

296 ing meal ingestion were used to assess small bowel water content (SBWC), colonic volumes, and T1 of t

297 Postprandial small-bowel water content showed a significant time by group i

298 always results in some dose delivered to the bowel with deleterious effects to the small and large in

299 deyer's ring, cervical lymph nodes, or small bowel with either nondestructive or polymorphic PTLD.

300 n of the entire mucosal surface of the small bowel with high-quality images, limited invasivity and a